original ) (raw )Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
Chi-li Chung
PLoS ONE, 2013
View PDFchevron_right
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer
Yukito Ichinose , Gouji Toyokawa
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2015
View PDFchevron_right
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Jin-Hyuk Choi
The Korean journal of internal medicine, 2017
View PDFchevron_right
Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer
Yoshihisa Shimada
Journal of Thoracic Disease, 2017
View PDFchevron_right
The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer
Chao Huang
Clinical Medicine Insights. Oncology, 2012
View PDFchevron_right
Survival Rate in Lung Adenocarcinoma with Mutation of the EGFR Gene with Tyrosine Kinase Inhibitor Treatment
noni soeroso
Open Access Macedonian Journal of Medical Sciences
View PDFchevron_right
The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
Po-Lan Su
Scientific Reports
View PDFchevron_right
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
Tse Hung Huang
Biomedical journal, 2016
View PDFchevron_right
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Maria Barzelloni
Clinical lung cancer, 2017
View PDFchevron_right
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-ares
Journal of Cellular and Molecular Medicine, 2010
View PDFchevron_right
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Lukas Amler
Cold Spring Harbor Symposia on Quantitative Biology, 2005
View PDFchevron_right
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
Elena Dragioti
DOAJ (DOAJ: Directory of Open Access Journals), 2021
View PDFchevron_right
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Farah Fatmawati
Asian Journal of Oncology, 2018
View PDFchevron_right
Comparison of Treatment Outcome in EGFR Positive and Negative Patients with Non Small Cell Lung Cancer: A Longitudinal Study
Zuber Ahmad
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
View PDFchevron_right
Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial
anuradha choughule
Indian Journal of Medical and Paediatric Oncology, 2018
View PDFchevron_right
Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER
Ping Li
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2011
View PDFchevron_right
Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations
Emmanuel De Laere , Elke Boone
Molecular Diagnosis & Therapy, 2015
View PDFchevron_right
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations
Mitsugu Omasa
International journal of clinical oncology, 2015
View PDFchevron_right
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer
S. Rampal
Lung Cancer, 2013
View PDFchevron_right
Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
Venceslau Hespanhol
Archivos de bronconeumologia, 2017
View PDFchevron_right
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement
Barbara Melosky , Flora Krasnoshtein
Current oncology (Toronto, Ont.), 2009
View PDFchevron_right
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
Tetsuya Mitsudomi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Survival Rate Comparison of Non Small Cell Lung Carcinoma Patients Who Are Given by Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor and Those Given by First-Line Chemotherapy Treatment
Hasan Nyambe
Nusantara Medical Science Journal, 2022
View PDFchevron_right
Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Sahrun Sahrun
Folia Medica Indonesiana, 2019
View PDFchevron_right
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
Massimo Rugge
Oncotarget, 2017
View PDFchevron_right
Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
mingyang liu
Journal of thoracic disease, 2016
View PDFchevron_right
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Maria Arcila
Clinical Cancer Research, 2011
View PDFchevron_right
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
Petra Nederlof , Alexandre Mathy , Sjaak Burgers
Annals of Oncology, 2006
View PDFchevron_right
Dynamic Changes of EGFR Activating Mutations as an Early Predictor of Progression in Non–Small Cell Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors
Katja Mohorcic
2020
View PDFchevron_right
Survival Rate of Lung Adenocarcinoma Patients Receiving EGFR - Tyrosine Kinase Inhibitor Targeted Therapy
Chaerani Bahar
Jurnal Kedokteran Brawijaya
View PDFchevron_right
EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: How do we interpret the clinical and biomarker data?
Fiona Blackhall
Targeted Oncology, 2008
View PDFchevron_right
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Charles Rudin
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018
View PDFchevron_right
CLINICAL CASE STUDY EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression
devi efrina
View PDFchevron_right